-
The competing risk approach for prediction of preeclampsia.
Wright D, Wright A, Nicolaides KH.
Am J Obstet Gynecol 2020;223:12-23.e7. pdf -
Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Bardani E, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;56:408-415. pdf -
Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Da Silva AB, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;56:400-407. pdf -
Mini-combined test compared with NICE guidelines for early risk-assessment for pre-eclampsia: the SPREE diagnostic accuracy study.
Poon LC, Wright D, Thornton S, Akolekar R, Brocklehurst P, Nicolaides KH.
Southampton (UK): NIHR Journals Library 2020 pdf -
Impact of new definitions of pre-eclampsia on incidence and performance of first-trimester screening.
Khan N, Andrade W, De Castro H, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;55:50-57. pdf -
Establishing a Differential Marker Profile for Pregnancy Complications Near Delivery.
Sharabi-Nov A, Kumar K, Fabjan Vodušek V, Premru Sršen T, Tul N, Fabjan T, Meiri H, Nicolaides KH, Osredkar J.
Fetal Diagn Ther 2020;47:471-484. pdf -
Competing-risks model for prediction of small-for-gestational-age neonates from maternal characteristics, serum PAPP-A and PlGF at 11-13 weeks' gestation.
Papastefanou I, Wright D, Lolos M, Anampousi K, Mamalis M, Nicolaides KH.
Ultrasound Obstet Gynecol 2021;57:392-400 pdf -
First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus.
Syngelaki A, Kotecha R, Pastides A, Wright A, Nicolaides KH.
Metabolism 2015;64:1485-9. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013;33:16-27. -
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013;33:164-72. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15.